165 related articles for article (PubMed ID: 2821650)
1. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
Agarwal KC; Buckley RS; Parks RE
Thromb Res; 1987 Jul; 47(2):191-200. PubMed ID: 2821650
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
Dawicki DD; Agarwal KC; Parks RE
Thromb Res; 1986 Jul; 43(2):161-75. PubMed ID: 3016942
[TBL] [Abstract][Full Text] [Related]
3. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine.
Dawicki DD; Agarwal KC; Parks RE
Biochem Pharmacol; 1985 Nov; 34(22):3965-72. PubMed ID: 4062970
[TBL] [Abstract][Full Text] [Related]
4. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
Ruppert D; Weithmann KU
Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
[TBL] [Abstract][Full Text] [Related]
5. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep.
Agarwal KC; Zielinski BA; Maitra RS
Thromb Haemost; 1989 Feb; 61(1):106-10. PubMed ID: 2749584
[TBL] [Abstract][Full Text] [Related]
6. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.
McElroy FA; Philip RB
Life Sci; 1975 Nov; 17(9):1479-93. PubMed ID: 173959
[No Abstract] [Full Text] [Related]
7. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
Azuma H; Takashima Y; Ishikawa M; Yamakado T
Jpn J Pharmacol; 1984 Feb; 34(2):159-70. PubMed ID: 6205194
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
Martinez GR; Walker KA; Hirschfeld DR; Bruno JJ; Yang DS; Maloney PJ
J Med Chem; 1992 Feb; 35(4):620-8. PubMed ID: 1311763
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity.
De La Cruz JP; Ortega G; Sánchez de la Cuesta F
Biochem Pharmacol; 1994 Jan; 47(2):209-15. PubMed ID: 8304965
[TBL] [Abstract][Full Text] [Related]
10. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation.
Meanwell NA; Roth HR; Smith EC; Wedding DL; Wright JJ; Fleming JS; Gillespie E
J Med Chem; 1991 Sep; 34(9):2906-16. PubMed ID: 1654430
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
Beretz A; Briançon-Scheid F; Stierlé A; Corre G; Anton R; Cazenave JP
Biochem Pharmacol; 1986 Jan; 35(2):257-62. PubMed ID: 3002388
[TBL] [Abstract][Full Text] [Related]
12. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
13. Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone.
Patelunas DM; Carmint WJ; Willis JZ; Colatsky TJ; Fenichel RL
Thromb Res; 1991 Jun; 62(5):389-400. PubMed ID: 1896959
[TBL] [Abstract][Full Text] [Related]
14. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233.
Tzanakakis GN; Agarwal KC; Vezeridis MP
Cancer; 1993 Apr; 71(8):2466-71. PubMed ID: 8453569
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.
Meanwell NA; Pearce BC; Roth HR; Smith EC; Wedding DL; Wright JJ; Buchanan JO; Baryla UM; Gamberdella M; Gillespie E
J Med Chem; 1992 Jul; 35(14):2672-87. PubMed ID: 1321910
[TBL] [Abstract][Full Text] [Related]
16. Relation between the inhibition of aggregation and the concentration of cAMP in human and rat platelets.
Michel H; Caen JP; Born GV; Miller R; D'Auriac GA; Meyer P
Br J Haematol; 1976 May; 33(1):27-38. PubMed ID: 178342
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.
Gresele P; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1986 Feb; 55(1):12-8. PubMed ID: 3704998
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
19. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
20. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Liu Y; Cone J; Le SN; Fong M; Tao L; Shoaf SE; Bricmont P; Czerwiec FS; Kambayashi J; Yoshitake M; Sun B
J Cardiovasc Pharmacol; 2004 Aug; 44(2):266-73. PubMed ID: 15243309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
